Skip to content

Phase II Growth and Safety Study of an Infant Formula for Healthy Term Infants

Phase II Growth and Safety Study of an Infant Formula for Healthy Term Infants

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04593147
Enrollment
131
Registered
2020-10-19
Start date
2020-10-14
Completion date
2021-11-09
Last updated
2021-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant Development

Brief summary

A goal of infant formula development is to mimic human milk (HM) both in nutrient composition as well as physiologic outcomes. investigators have developed an infant formula for term infants that more closely resembles the composition of human milk. The purpose of this study is to demonstrate that this formulation meets nutritional requirements and supports age appropriate growth of healthy term infants.

Detailed description

This study is a randomized, controlled, double-blind, study of healthy term formula fed (FF) infants. FF infants will be randomized to receive either a experimental infant formula, formulated for healthy term infants (BBN) or a commercially available infant formula for healthy term infants (Brand). Infants will consume the formula for a total of 16-weeks; infant growth, serum markers for inflammation and tolerance to the formulas will be assessed throughout the study.

Interventions

OTHERBBN

BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.

OTHERBrand

Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks

Sponsors

Paidion Research, Inc.
CollaboratorINDUSTRY
Building Block Nutritionals, LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

This study is a randomized, controlled, double-blind, study of healthy term formula fed (FF) infants.

Intervention model description

Formula feed infants will be randomized to receive either a new infant formula formulated for healthy term infants (BBN) or a commercially available infant formula for healthy term infants (Brand). Infants will consume the formula for a total of 16-weeks.

Eligibility

Sex/Gender
ALL
Age
1 Days to 14 Days
Healthy volunteers
Yes

Inclusion criteria

Infants will be eligible to participate if they meet all of the following conditions. At birth, the infant must be: Inclusion Criteria: * Healthy, term (early term/no less than 37 weeks, 0 days through late term/no greater than 41 weeks, 6 days), singleton infant * Have a birth weight of ≥ 2500 grams * Designated as healthy by a physician * ≤14 days post-natal age (Date of Birth = Day 0) * Weight for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts * Length for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts * Head circumference for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts * Weight for length for age ≥ 5th and ≤ 95th percentile for age according to sex-specific World Health Organization (WHO) growth charts * Exclusively consuming and tolerating a cow's milk infant formula at time of enrollment * Only infants whose parent(s) or legal guardian(s) have decided to feed infant formula as the sole source of nutrition, will be approached for potential study enrollment * Have parent(s) or legal guardian(s) who agree to feed the study formula to the study subject as his/her sole source of nutrition for the duration of the study * Have parent(s) or legal guardian(s) who have read and voluntarily signed an Informed Consent form approved by the Institutional Review Board prior to any participation in the study. Infants will be ineligible if they have any of the following conditions that are judged by a physician to interfere with the infant's normal growth, development, and/or tolerance to an infant formula:

Exclusion criteria

* Infants will be ineligible if they have any of the following conditions that are judged by a physician to interfere with the infant's normal growth, development, and/or tolerance to an infant formula * Show evidence of anatomic and physiologic defects of the respiratory tract, or other congenital defects (as determined by the clinician); * Show evidence of chronic hepatic, gastrointestinal, renal, cardiac, pulmonary, or neurological diseases; * Have a maternal history with known adverse effects on the fetus and/or the newborn infant, such as diabetes (gestational diabetes is acceptable if infant's birth weight is \< 4300 g), active tuberculosis, perinatal infection, or substance abuse * Have a family history of cow's milk protein intolerance/allergy * Are an infant from a multiple birth (twin, triplet, etc.)

Design outcomes

Primary

MeasureTime frameDescription
Weight gain16 weeksChange grams per day

Secondary

MeasureTime frameDescription
Mean fussiness score16 weeks0= less fussy than normal, 1= about the same level of fussiness as normal, 2= more fussy than normal
Mean gassiness score16 weeks0= no gas, 1= slight amount of gas, 2= moderate amount of gas, 3= excessive amount of gas
Mean stool consistency16 weeks1= watery, 2= runny / soft, 3= mushy / soft, 4= formed soft, 5= hard
Mean interleukin - 10 Concentration16 weeksIL - 10 pg/ml
Mean tumor necrosis factor alpha concentration16 weeksTNF - alpha pg/ml
Mean interleukin - 6 Concentration16 weeksIL - 6 ng/ml

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026